Diuretics and digitalis in the treatment of chronic heart failure.
The evaluation of the long-term treatment of heart failure is complicated by many biological, clinical and technical problems. Chronic heart failure results from a variety of causes, each resulting in fundamentally different histopathological profiles. Once established chronic heart failure is unremitting, but the speed of progression of the haemodynamic derangement varies widely between different individuals. Moreover, the extent of the haemodynamic disorder correlates poorly with the severity of symptoms. The metabolism of drugs and the response of the damaged myocardium to these drugs is often quite different in the patient with heart failure than in the normal subject. Finally chronic heart failure is a terminal condition of relatively short duration so that clinical trials designed to test the efficacy of a drug treatment will fail if they are continued for more than a brief period, as all patients will die. It is against this complex biological background that the long-term clinical efficacy of diuretics and digitalis in the treatment of chronic heart failure must be evaluated.
D000284:Administration, Oral; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004077:Digoxin / Q000008:administration & dosage*; D004232:Diuretics / Q000008:administration & dosage*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D011379:Prognosis; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D004232:Diuretics; D004077:Digoxin